The buzz around the Corona Remedies IPO has been building steadily—and Day 1 of the public issue has only amplified the interest. As the pharma company opens its ₹655.37 crore public offer, investors across the retail, QIB, and NII segments are tuning in to understand what the issue looks like, what the numbers say, and how the subscription progress unfolds.
Market Performance: Sentiment Around Corona Remedies IPO
The broader market has been steady, but IPO-specific chatter has been more active, especially around the Corona Remedies IPO, Corona Remedies IPO subscription status, and Corona Remedies IPO price band.
On Day 1, participation from retail and institutional pockets began flowing in from 11 AM onward, marking the start of the three-day window.
Corona Remedies IPO: What’s Opening Today
The Corona Remedies IPO opened on December 8 and will remain available for public subscription until December 10.
The company is looking to raise ₹655.37 crore through an Offer for Sale (OFS) of 0.62 crore shares. Since it’s a pure OFS, the company itself will not receive capital from the issue; the proceeds are meant for existing shareholders who are partially exiting.
Key IPO Numbers
- Issue Size: ₹655.37 crore
- Type: 100% Offer for Sale
- Shares Offered: 0.62 crore
- Price Band: ₹1,008 – ₹1,062 per share
- Retail Lot Size: 14 shares
- Minimum Investment (upper band): ₹14,868
- Bid Multiples: 14 shares
Reservation Breakdown
- Retail Investors: 35%
- Qualified Institutional Buyers (QIBs): 50%
- Non-Institutional Investors (NIIs): 15%
This structure keeps the public offer balanced, allowing each category its proportionate participation.
Corona Remedies IPO Subscription Status: Day 1 Begins
The Corona Remedies IPO subscription window kicked off at 11 AM on Day 1. Interest across categories began building through the day as investors submitted bids within the set price band.
While the subscription numbers will evolve until December 10, the opening day activity indicates steady demand across retail and institutional categories.
Company Details: Inside Corona Remedies
Corona Remedies is a Gujarat-based pharmaceutical manufacturer operating across a wide span of therapeutic segments. Over the years, the company has scaled steadily across chronic and sub-chronic categories.
Business Presence
- Women's healthcare
- Cardio-diabetes
- Pain management
- Urology
- Other therapeutic segments
Manufacturing Footprint
- Unit 1: Gujarat
- Unit 2: Himachal Pradesh
Both locations contribute to the company’s broad product portfolio and distribution scale.
Financial Performance: Revenue & Profit Snapshot
Corona Remedies has displayed consistent growth over the past years, supported by expansion across product categories and market share stability.
Below is the financial data provided in the RHP:
Revenue
- FY25 Revenue: ₹1,196.41 crore
- FY26 (Q2) Revenue from operations: ₹346.54 crore
Net Profit
- FY25 Net Profit: ₹149.43 crore
- FY26 (Q1) Net Profit: ₹46.19 crore
These numbers outline a steady performance curve, offering a clear view of the company's recent trajectory.
Anchor Investment Before the IPO
Ahead of the IPO launch, the company raised ₹194.85 crore through the anchor book from 15 institutional investors. This allocation took place prior to the public opening, in line with standard IPO procedure.
Key Dates to Track
Here’s a quick timeline for anyone following the Corona Remedies IPO closely:
Important IPO Milestones
- IPO Opens: December 8
- IPO Closes: December 10
- Basis of Allotment: December 11
- Refund Initiation: December 12
- Shares Credited to Demat: December 12
- Listing Date: December 15
- Exchanges: BSE & NSE
Keeping these dates in mind helps investors track allotment updates and listing developments smoothly.
Summary
The Corona Remedies IPO arrives with a clear structure ₹655.37 crore fully through OFS, a price band of ₹1,008–1,062, and a three-day subscription window. With a presence across major pharma therapies, two manufacturing units, and consistent revenue and profit growth, the IPO has naturally drawn attention on Day 1.
Retail investors, QIBs, and NIIs all participate proportionately under the reserved quota system, while the listing is scheduled for December 15 on both exchanges.
Easy & quick
Leave A Comment?